bioRxivMicrobiologyPreprint
Nanobodies against Plasmodium vivax AMA1 block parasite invasion
Jill ChmielewskiiD, Li-Jin ChaniD, Li Lynn TaniD, Jaison D SaiD, Amy AdairiD, Jerry Jiaheng Chen, Chunyi QianiD, Phillip PymmiD, Frankie M T LyonsiD, Kathleen ZeglinskiiD, James G BeesoniD, Christopher L King, Wai-Hong ThamiD, Melanie H DietrichiD
Abstract
Plasmodium vivax is the most widespread malaria species to infect human populations. P. vivax invades young red cells called reticulocytes to replicate and proliferate. An essential protein in parasite invasion is the Apical Membrane Antigen 1, PvAMA1, which forms the tight junction between parasite and red cell membrane through its interaction with Rhoptry Neck Protein 2, PvRON2. Here we report the identification of PvAMA1 nanobodies using phage display in combination with Sanger sequencing, next-generation sequencing and structure prediction tools. We show that these nanobodies bind with high affinities and across several different epitopes on PvAMA1. Several nanobodies recognize PvAMA1 in merozoites of late-stage schizonts and inhibit parasite invasion of red blood cells. These growth inhibitory nanobodies bind to conformational epitopes of PvAMA1 and most bind to a site distinct from a known potent human monoclonal antibody 826827. Crystal structures of two inhibitory nanobodies in complex with PvAMA1 show that they bind novel neutralizing epitopes which are outside the hydrophobic groove that contacts PvRON2. Furthermore, we show that two other PvAMA1 nanobodies also inhibit Plasmodium falciparum invasion. These results demonstrate the potential of PvAMA1 nanobodies to inhibit malaria parasite invasion across multiple Plasmodium species.
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
A. C. Winnicki, C. L. King, … B. K. Wilder·bioRxiv·Feb 7, 2024
- Nanobodies against Plasmodium adhesins that block receptor engagement and malaria parasite invasion
Jaison D Sa, Jill Chmielewski, … Wai‐Hong Tham·Biochemical JournalPeer-reviewed·Jul 1, 2026
- Functional analysis of novel microneme proteins from Plasmodium vivax blood stages identifies vaccine candidates
Arunaditya Deshmukh, Francisco José Martínez Martínez, … Chetan E. Chitnis·bioRxiv·Aug 7, 2026
- The reticulocyte restriction: invasion ligand RBP1a of Plasmodium vivax targets human TfR1, prohibitin-2, and basigin
Jessica Molina-Franky, Daniel Röth, … Markus Kalkum·Frontiers in Cellular and Infection MicrobiologyPeer-reviewed·Sep 25, 2025
- Naturally acquired blocking human monoclonal antibodies to Plasmodium vivax reticulocyte binding protein 2b
L.-J. Chan, A. Gandhirajan, … W.-H. Tham·bioRxiv·May 12, 2020
- PfAMA1-expressing chimeric rodent malaria parasites provide an in vivo platform for evaluating multistage interventions against malaria
Quratul-ain Issahaque, Naoaki Shinzawa, … Tomoko Ishino·bioRxiv·Aug 30, 2026